These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7475755)

  • 1. Neuroprotective mechanism of bromocriptine.
    Yamashita H; Kawakami H; Zhang YX; Tanaka K; Nakamura S
    Lancet; 1995 Nov; 346(8985):1305. PubMed ID: 7475755
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroprotection in Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Lancet; 1996 Jan; 347(8995):196. PubMed ID: 8544568
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuroprotection in PD--a role for dopamine agonists?
    Schapira AH
    Neurology; 2003 Sep; 61(6 Suppl 3):S34-42. PubMed ID: 14504378
    [No Abstract]   [Full Text] [Related]  

  • 4. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.
    Kitamura Y; Taniguchi T; Shimohama S; Akaike A; Nomura Y
    Neurochem Res; 2003 Jul; 28(7):1035-40. PubMed ID: 12737528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer therapies for Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Neurol Neurochir Pol; 1996; 30 Suppl 2():105-11. PubMed ID: 9100248
    [No Abstract]   [Full Text] [Related]  

  • 6. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical versus clinical neuroprotection.
    Grünblatt E; Schlösser R; Gerlach M; Riederer P
    Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
    [No Abstract]   [Full Text] [Related]  

  • 8. New directions in the drug treatment of Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

  • 10. Eight-year follow-up study of bromocriptine monotherapy for Parkinson's disease.
    Tashiro K; Goto I; Kanazawa I; Kowa H; Kuno S; Mizuno Y; Ogawa N; Yanagisawa N
    Eur Neurol; 1996; 36 Suppl 1():32-7. PubMed ID: 8791019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocriptine therapy in early-stage Parkinson's disease.
    Fukuyama H; Kawamura J; Akiguchi I; Kimura J; Imai T
    Eur Neurol; 1996; 36(3):164-70. PubMed ID: 8738948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial agonist treatment of Parkinson disease: a critique.
    Albin RL; Frey KA
    Neurology; 2003 Feb; 60(3):390-4. PubMed ID: 12580185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
    Pullan PT
    Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
    [No Abstract]   [Full Text] [Related]  

  • 16. Attempts to obtain neuroprotection in Parkinson's disease.
    Olanow CW
    Neurology; 1997 Jul; 49(1 Suppl 1):S26-33. PubMed ID: 9222272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials of neuroprotection for Parkinson's disease.
    LeWitt PA
    Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
    [No Abstract]   [Full Text] [Related]  

  • 18. The comparative effects of medical therapies for Parkinson's disease.
    Horn S; Stern MB
    Neurology; 2004 Oct; 63(7 Suppl 2):S7-12. PubMed ID: 15477585
    [No Abstract]   [Full Text] [Related]  

  • 19. Pergolide mesylate in Parkinson's disease treatment.
    Pezzoli G; Canesi M; Pesenti A; Mariani CB
    J Neural Transm Suppl; 1995; 45():203-12. PubMed ID: 8748627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.